Sinovac Research and Development Co., Ltd.

Quick facts

Marketed products

• Experimental vaccine 1
• Experimental vaccine 2
• Experimental vaccine 3
• Inactivated COVID-19 Vaccine · Immunology
  This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting inactivated viral particles.
• Inactivated SARS-CoV-2 Vaccine (Vero cell） · Immunology / Infectious Disease
  This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting whole inactivated viral particles.
• The SARS-CoV-2 Inactivated Vaccine

Phase 3 pipeline

• control live attenuated mumps vaccine · Immunology
  The control live attenuated mumps vaccine works by introducing a weakened form of the mumps virus to stimulate an immune response.
• Controlled vaccine · Immunology
  A vaccine that stimulates the immune system to recognize and respond to specific disease antigens.
• COVID-19 Vaccine,Inactivated · Immunology
  An inactivated viral vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting inactivated virus particles.
• Investigational live attenuated mumps vaccine · Immunology
  A live attenuated mumps vaccine stimulates the immune system to recognize and protect against mumps virus infection by using a weakened form of the virus.
• Sinovac PCV13 · Immunology
  Sinovac PCV13 is a vaccine that stimulates the body's immune response to protect against 13 serotypes of pneumococcal disease.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sinovac Research and Development Co., Ltd. portfolio CI brief
• Sinovac Research and Development Co., Ltd. pipeline updates RSS